Chembio applies for CLIA waiver for HIV test
This article was originally published in Clinica
Chembio Diagnostics has submitted study data to the US FDA as part of an application for a CLIA waiver for its diagnostic test for HIV. The information is part of an amendment to the firm's 2006 submission to the Center for Devices and Radiological Health division of the agency.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.